Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration
详细信息 查看全文
- 作者：Sarah Perreault ; Julie Baker ; Erin Medoff ; Kathryn Pratt…
- 关键词：Carmustine ; BEAM ; Infusion ; related reactions ; Autologous hematopoietic stem cell transplantation
- 刊名：Supportive Care in Cancer
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：25
- 期：1
- 页码：205-208
- 全文大小：
- 刊物类别：Medicine
- 刊物主题：Oncology; Nursing; Nursing Research; Pain Medicine; Rehabilitation Medicine;
- 出版者：Springer Berlin Heidelberg
- ISSN：1433-7339
- 卷排序：25
文摘
PurposeCarmustine (BCNU) is used in the conditioning regimens BEAM and CBV for autologous stem cell transplantation. Carmustine-related infusion reactions, while not described in the BEAM literature, occurred in 95 % of patients who received CBV. The most common symptoms include flushing, facial pain, headache, and hypotension. These reactions have been attributed to the absolute ethanol that is used in the reconstitution process or alternatively by a direct effect of carmustine. It is currently recommended that carmustine 300 mg/m2 be infused over at least 100 min (3–5 mg/m2/min). Prior to October 2014, carmustine infusions were given over 90 min but were changed to 120 min based on the above recommendation. We compared the two infusion rates in patients receiving BEAM to see if lengthening the infusion decreased the frequency of reactions.